Integrin α6-targeted SPECT Imaging of Breast Cancer

• Status: Completed
• Trial end date: 2019-06-30
• Target enrollment: 0
• Participant gender: All

Summary

A novel radiotracer 99mTc-RWY targeting Integrin α6 was developed, and the pilot first-in-human study for SPECT imaging of breast cancer was performed in seven healthy volunteers and two breast cancer patients to assess the safety and potential clinical applications of 99mTc-RWY.

• Phase: Early Phase 1
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Bing Jia; Peking University
• Collaborators: China-Japan Union Hospital, Jilin University; Sun Yat-sen University

Criteria

Inclusion criteria:

• Healthy volunteers.

• Body mass index (BMI) at 19 to 25 [Body mass index = body weight (kg)/ height squared (m2)];

• Clinical laboratory tests (heart, liver, kidney, blood) indicators are in the normal range or abnormalities without clinical significance;

• Informed written consents were obtained from all 9 subjects before the procedure.

• Patients in suspicion of breast cancer by mammography or ultrasonography, and being able to provide basic information.

Exclution Criteria:

• The investigator judged that it is not suitable for clinical trials based on the overall situation of the volunteers and patients.